Key result
Heart failure trial endpoints have evolved from all-cause mortality in 1000-2000 patients with functional class III-IV symptoms to composite endpoints in 3000-5000 patients with functional class II symptoms.
Answers are grounded in this paper and cite their sources.
This editorial critiques the evolution of heart failure trial designs, particularly the shift towards composite endpoints and the win ratio to reduce sample sizes and follow-up duration.
Medical research must be designed to provide definitive evidence about the long-term efficacy and safety of any treatment.Yet, many trial sponsors and investigators are attracted to proposals that involve studying the fewest number of patients for the shortest period of time.In the last 25 years of the 20th century, the primary endpoint for a heart failure trial was all-cause mortality, evaluated in trials 1000-2000 patients with New York Heart Association (NYHA) class III-IV symptoms.During the first 25 years of the 21st century, the primary endpoint moved to a composite of cardiovascular death and worsening heart failure events, involving the enrolment of 3000-5000 patients, primarily with NYHA class II symptoms.These trials also evaluated symptoms and functional measurements as secondary endpoints, but a drug that impacts morbidity and mortality may have meager effects on health status.
No takes yet. Share an insight, caveat, or question.
Packer et al. (2025) conducted an editorial in Heart failure. Heart failure trial endpoints have evolved from all-cause mortality in 1000-2000 patients with functional class III-IV symptoms to composite endpoints in 3000-5000 patients with functional class II symptoms.
Synapse has enriched 10 related papers. Consider them for comparative context: